InMed Pharmaceuticals Inc. (NASDAQ: INM)

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0001728328
Market Cap 1.96 Mn
P/B 0.20
P/E -0.26
P/S 0.44
ROIC (Qtr) -71.25
Div Yield % 0.00
Rev 1y % (Qtr) -26.22
Total Debt (Qtr) 408,122.00
Debt/Equity (Qtr) 0.04
Add ratio to table...

About

Investment thesis

Bull case

  • Healthy cash reserves of 6.95M provide 17.04x coverage of short-term debt 408122, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 9.65M provides 23.65x coverage of total debt 408122, indicating robust asset backing and low credit risk.
  • Cash reserves of 6.95M provide solid 56.17x coverage of other non-current liabilities 123827, indicating strong liquidity.
  • Cash reserves of 6.95M provide robust 4.70x coverage of current liabilities 1.48M, indicating strong short-term solvency.
  • Cash reserves of 6.95M exceed inventory value of 947898 by 7.34x, indicating strong liquidity and inventory management.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 2.23M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (7.42M) shows concerning coverage of stock compensation expenses of 112653, with a -65.88 ratio indicating potential earnings quality issues.
  • Operating earnings of (7.64M) show weak coverage of depreciation charges of 575364, with a -13.29 ratio indicating high capital intensity and potential reinvestment needs.
  • Operating cash flow of (7.42M) barely covers operating expenses of 211461 with a -35.10 ratio, suggesting thin operational efficiency margins and limited flexibility.
  • Retained earnings of (120.99M) provide limited buffer against comprehensive income items of 128569, which is -941.07x, indicating elevated exposure to market risks.

Subsegments Breakdown of Revenue (2025)

Subsegments Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ZTS Zoetis Inc. 59.62 Bn 29.27 7.67 9.24 Bn
2 TAK Takeda Pharmaceutical Co Ltd 57.33 Bn 79.02 2.00 36.56 Bn
3 HLN Haleon plc 51.85 Bn 33.06 3.83 -
4 TEVA Teva Pharmaceutical Industries Ltd 39.45 Bn 27.98 2.29 17.09 Bn
5 UTHR UNITED THERAPEUTICS Corp 21.54 Bn 16.94 6.89 0.00 Bn
6 RGC Regencell Bioscience Holdings Ltd 16.16 Bn -4,510.00 0.00 -
7 ELAN Elanco Animal Health Inc 12.79 Bn 355.14 2.78 4.32 Bn
8 NBIX Neurocrine Biosciences Inc 12.71 Bn 26.56 4.44 0.42 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets -0.62 38.12
EV to Cash from Ops. EV/CFO 0.94 -121.97
EV to Debt EV to Debt -17.01 403.43
EV to EBIT EV/EBIT 0.91 -55.05
EV to EBITDA EV/EBITDA 0.96 -57.64
EV to Free Cash Flow [EV/FCF] EV/FCF 0.94 -65.56
EV to Market Cap EV to Market Cap -3.54 -4.24
EV to Revenue EV/Rev -1.54 -1,205.44
Price to Book Value [P/B] P/B 0.20 43.48
Price to Earnings [P/E] P/E -0.26 -46.00
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 0.36
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.52
Dividend per Basic Share Div per Share (Qtr) 0.00 0.07
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 4.04
Interest Coverage Int. cover (Qtr) -382.22 -46.13
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 -154.90
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 103.39 86,151.29
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 2.89
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -1.09 31.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) -1.08 9.88
EBIT Growth (1y) % EBIT 1y % (Qtr) -1.19 91.77
EBT Growth (1y) % EBT 1y % (Qtr) 3.06 90.13
EPS Growth (1y) % EPS 1y % (Qtr) 75.57 -12.06
FCF Growth (1y) % FCF 1y % (Qtr) -1.77 -224.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -21.65 26.23
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.40 0.49
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 4.70 2.12
Current Ratio Curr Ratio (Qtr) 5.94 3.92
Debt to Equity Ratio Debt/Equity (Qtr) 0.04 -1.15
Interest Cover Ratio Int Coverage (Qtr) -382.22 -46.13
Times Interest Earned Times Interest Earned (Qtr) -382.22 -46.13
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -156.90 -59,714.97
EBIT Margin % EBIT Margin % (Qtr) -169.63 -60,539.44
EBT Margin % EBT Margin % (Qtr) -170.07 -64,118.78
Gross Margin % Gross Margin % (Qtr) 29.70 8,658.69
Net Profit Margin % Net Margin % (Qtr) -170.10 -64,120.53